LKB1, mutated in Peutz-Jeghers and in sporadic lung tumours, phosphorylates a group of protein kinases named AMP-activated protein kinase (AMPK)-related kinases. Among them is included the AMPK, a sensor of cellular energy status. To investigate the relevance of LKB1 in lung carcinogenesis, we study several lung cancer cells with and without LKB1-inactivating mutations. We report that LKB1-mutant cells are deficient for AMPK activity and refractory to mTOR inhibition upon glucose depletion but not growth-factor deprivation. The requirement for wild-type LKB1 to properly activate AMPK is further demonstrated in genetically modified cancer cells. In addition, LKB1-deficient lung primary tumours had diminished AMPK activity, assessed by complete absence or low level of phosphorylation of its critical substrate, acetyl-CoA carboxylase. We also demonstrate that LKB1 wild-type cells are more resistant to cell death upon glucose withdrawal than their mutant counterparts. Finally, modulation of AMPK activity did not affect PI3K/AKT signalling, an advantage for the potential use of AMPK as a target for cancer therapy in LKB1 wildtype tumours. Thus, sustained abrogation of cell energetic checkpoint control, through alterations at key genes, appear to be an obligatory step in the development of some lung tumours.
Introduction
Germ line mutations of LKB1, also known as STK11, give rise to Peutz-Jeghers syndrome (PJS) (Hemminki et al., 1998; Jenne et al., 1998) , characterized by pigmentation anomalies, development of hamartomas and increased risk of cancer (Jeghers et al., 1949; Giardiello et al., 1987) . We recently discovered that LKB1 is also somatically inactivated in sporadic lung adenocarcinomas (Sanchez-Cespedes et al., 2002) , a clear evidence that LKB1 mutations are not circumscribed to the PJS.
LKB1 is a serine-threonine kinase that functions in a heterotrimeric complex with the inactive pseudokinase, STE20-related adaptor (STRAD) and the armadillo repeat scaffolding-like protein, MO25. The latter stabilizes the binding of STRAD to LKB1 and relocalizes LKB1 from the nucleus to the cytoplasm Boudeau et al., 2003) .
Several studies have demonstrated that ectopic LKB1 can suppress the growth of LKB1-deficient tumour cells (Tiainen et al., 1999; Karuman et al., 2001; Jimenez et al., 2003) . LKB1 also controls the regulation of VEGF and Cox-2 expression (Ylikorkala et al., 2001; Rossi et al., 2002) . As happens in the PJS, Lkb1 heterozygous mice show gastrointestinal hamartomas and hepatocellular carcinomas (Nakau et al., 2002) . Vascular abnormalities have also been reported (Ylikorkala et al., 2001) .
LKB1 functions as a master upstream kinase of a group of protein kinases named AMPK-related kinases, homologous to the AMP-activated protein kinase. The most studied substrate of LKB1 is AMPK itself (Hawley et al., 2003; Woods et al., 2003) , a sensor of cellular energy status that is activated by phosphorylation at Thr 172 in the presence of high levels of AMP (Hardie, 2003) . Several physiological and pathological stresses lead to AMPK activation, including exercise, hypoxia, ischaemia, heat shock and low glucose. Upon activation, AMPK phosphorylates multiple downstream targets to normalize adenosine triphosphate (ATP) levels, including acetyl-CoA carboxylase (ACC). Interestingly, AMPK can also phosphorylate and activate the tuberin protein (or TSC2), the product of the tuberous sclerosis complex 2 gene (TSC2) (Inoki et al., 2003) , and LKB1 is required for the repression of mTOR under low ATP conditions in cultured cells in an AMPK-and TSC2-dependent manner (Brugarolas et al., 2004; Corradetti et al., 2004) . Mutations of TSC1 and TSC2 genes are linked to the tuberous sclerosis syndrome, which shares similarities with the PJS, including the presence of hamartomas (Consortium TECS, 1993) . TSC2 binds to the TSC1 protein, forming a functional complex that inhibits the phosphorylation of S6K and 4EBP, two key regulators of translation (reviewed by Manning and Cantley, 2003) .
In addition to AMPK, other LKB1 substrates include the MARK1-4 kinases implicated in the regulation of cell polarity (Lizcano et al., 2004) . This is consistent with the role of LKB1 in inducing complete polarity in intestinal epithelial cells (Baas et al., 2004) .
Here, we report our investigation of the biological characteristics of lung cancer cells carrying LKB1-inactivating mutations. Our results confirm that LKB1 regulates AMPK activity and demonstrate that LKB1 deficiency impairs inhibition of mTOR activity in response to agents that increase intracellular levels of AMP but not to the deprivation of growth factors.
Results

LKB1-mutant lung cancer cells are deficient in AMPK activity
The LKB1-mutant and wild-type lung cancer cells were assayed for their proficiency in AMPK activation. First, we generated a monoclonal antibody against LKB1. This specific antibody recognizes a unique band in the immunoblot at 52 kDa. Figure 1a depicts the absence or presence of LKB1 protein in LKB1-mutant and wild-type cells, respectively. The mutational status of other common cancer genes is also indicated. The antibody probably targets an epitope at the C-terminal region of the protein because no band could be detected when ectopic SL-8 protein (an LKB1 mutant from a Peutz-Jeghers individual lacking the C-terminal region) was introduced in LKB1-deficient lung cancer cells (data not shown). Consistent with this, neither was the LKB1 band observed in the H23 cells with a nonsense mutation at exon 8, which is predicted to encode for a shorter LKB1 protein that lacks the C-terminal region. STRADa is required to enhance LKB1 activity and cytosolic localization, so we first tested the levels of STRADa protein in our panel of cancer cell lines. As depicted in Figure 1a , LKB1 parallels STRADa protein expression. Low levels of STRADa protein were detected in LKB1-deficient cells, in contrast to their LKB1 wild-type counterparts (similar results were obtained by Baas and Clevers in A549, H23 and H522 cells; personal communication Figure 2a , several clones expressed inducible LKB1 in both types of cell. LKB1 protein was detectable after 12 h following induction with doxycyclin. For subsequent studies, we selected the H42-5/H42-19 and the A91-5/A91-7 clones from the H23 and A549 cells, respectively. Immunofluorescence ( Figure 2b ) confirmed that these clones had ectopic LKB1 expression in more than 90% of the cells (data not shown). STRADa protein is almost undetectable in the parental H23 and A549 cells, so we first tested the levels of STRADa upon reintroduction of wild-type LKB1. Interestingly, ectopic expression of LKB1 increased endogenous STRADa (Figure 2c ), indicating that the presence of LKB1 either prevents degradation of STRADa or promotes its gene transcription.
We next evaluated whether ectopic LKB1 restored AMPK activity in the presence of the appropriate stimuli. As shown in Figure 2c , glucose starvation lead to a considerable increase of pACC upon induction of LKB1 with doxycyclin in the clones. Deficient AMPK and energy stress in LKB1-mutant cells J Carretero et al
LKB1 depletion impairs AMPK activation upon glucose depletion or AICAR treatment
We evaluated the modifications in AMPK activation in lung cancer cells after depleting wild-type LKB1 by siRNA expression. To this end, we used a construct in the plasmid pTER carrying a sequence that had previously been demonstrated to downregulate LKB1 efficiently (Baas et al., 2004) . We performed a transient co-transfection assay of pTER-LKB1 and pGFP, followed by selection in a flow cytometric cell sorting. As determined by Western blotting, siRNA was able to downregulate LKB1 expression efficiently (Figure 2d ). Compared with the control, cells transfected with the pTER-LKB1 had decreased levels of pACC following treatment with AICAR. Some examples of these observations are also depicted in Figure 2d .
LKB1-deficient cells are refractory to mTOR inactivation in response to glucose but not upon deprivation of growth factors We tested the ability of LKB1-mutant and wild-type cells to inactivate mTOR signalling in response to energetic collapse. As a subrogate marker for mTOR activity, we used phospho-235/236 S6 ribosomal protein (pS6), a substrate of the translational regulator p70 ribosomal S6 kinase 1 (S6K), itself a downstream effector of mTOR. We found that mutant cells were highly resistant to mTOR inactivation, as measured by the levels of pS6, following glucose depletion or AICAR treatment ( Figure 3a) . Figure 3b shows the gradual increase and decrease in the levels of pACC and pS6, respectively, in the LKB1 wild-types Calu-3 and H441 but not in the LKB1 mutants A549 and H23 cells, following progressive decrease in glucose concentrations.
Given the dual role of mTOR in integrating signalling from nutrient availability and response to growth factors, we also studied the ability of LKB1-mutant and wild-type cells to affect mTOR activity on growthfactor starvation. We observed that the presence of LKB1 mutations did not affect the efficient inhibition of mTOR activity in the absence of growth factors, as indicated by the decrease in pAKT and pS6 levels when growth factors were removed from the culture (Figure 3c ). Conversely, LKB1 wild-type cells showed a variable ability to modulate mTOR activity under such circumstances. Constitutive activation of AKT is evident in the Calu-3 cells and was probably due to ErbB2 gene amplification. It is particularly worth noting that the LKB1 wild-type H1299 cells inhibit mTOR activity on growth factors but not glucose depletion.
LKB1-mutant lung primary adenocarcinomas have reduced levels of AMPK activity We also investigated whether this observations were reproduced in primary tumours. We performed immunostaining of LKB1 and pACC proteins in 37 lung primary adenocarcinomas, including seven tumours carrying LKB1 mutations leading to truncated protein (Fernandez et al., 2004) . Overall, 13 (35%) of the lung adenocarcinomas, including all LKB1 mutants, were negative for LKB1 immunostaining. Some examples are depicted in Figure 4a . Levels of pACC protein were categorized as absent/low or moderate/high according to the intensity of staining. According to this classification, 10 (77%) of the tumours negative and seven (29%) positive for LKB1 immunostaining, had absent/low pACC levels (P ¼ 0.007; Fisher exact test) (Figure 4b ). Complete activation of AMPK following glucose depletion rescue cell viability in LKB1wild-type cells To test whether the responses to conditions or drugs that interfere with the mTOR signalling were dependent on the status of the LKB1 gene, we evaluated the effect on cell proliferation and viability of lung cancer cells following treatment with AICAR, rapamycin and LY-294002. We observed that cell growth inhibition induced by each compound varied in the distinct cells but was independent of LKB1 gene status (examples for AICAR and rapamycin are shown in Figure 5a ). We also compared how AICAR treatment affected cell viability following glucose withdrawal in the distinct tumour cells. In contrast to their mutant counterparts, LKB1 wild-type cells showed significant reduced cell death after AICAR treatment (Figure 5b ). The inset shows how AICAR treatment under conditions of glucose depletion yielded maximum pAMPK levels in the Calu-3 cells. The effect was also evident after restoring wild-type LKB1 in deficient cells. To this end, we used the A549 and the H23 cells that were reconstituted with wild-type LKB1 and assayed the ability of AICAR or glucose depletion to affect cell proliferation. As indicated in Figure 5c , ectopic and stable wild-type LKB1 increased the number of cells. Examples of cell viability following AICAR treatment in glucose-depleted cells are depicted in Figure 5d . Thus, LKB1-mutant cells are sensitive to conditions that deplete available intracellular energy owing to their deficient AMPK activity.
Analysis of the functional interaction between LKB1/ AMPK and PI3K/AKT signalling in cancer cells
The presence of a negative feedback loop triggered by an overactivation of mTOR leads to the inhibition of insulin-responsive PI3K/AKT signalling. This inhibitory feedback occurs as a result of an mTOR-dependent phosphorylation of IRS-1 that uncouples its interaction with the insulin receptor (Manning, 2004 ). Here, we tested whether modulation of mTOR through LKB1/ AMPK affects PI3K/AKT signalling, as this may have Deficient AMPK and energy stress in LKB1-mutant cells J Carretero et al implications for the targeting of AMPK in cancer therapy. We first examined how ectopic expression of LKB1 in LKB1-deficient cancer cells exposed to distinct treatments influenced the levels of several components of the pathways. As expected, doxycyclin induction in the clones increased pAMPK activity and concomitantly reduced levels of pS6 upon AICAR activation but did not significantly increase AKT phosphorylation (Figure 6a and b) . Inhibition of mTOR activity by rapamycin notably activated AKT (Figure 6a ). The same observations were obtained for the H42-19 clone (Supplementary Figure 1) . Similarly, a progressive decrease in glucose concentration in the Calu-3 cells clearly activated AMPK and reduced levels of pS6, while pAKT remained constant (Figure 6c ). In Figure 6a , it is also observed that the LY-294002 compound decreased pAMPK and pACC levels. In fact, increasing LY-294002 concentration lead to a clear reduction of pACC and pAMPK levels in cancer cell lines (Supplementary Figure 2) . However, a nonspecific Deficient AMPK and energy stress in LKB1-mutant cells J Carretero et al effect of the compound on the activity of LKB1 cannot be discarded. On the other hand, increasing the concentration of the selective AMPK antagonist Compound C (CC), in the constitutive-PI3K-AKT active Calu-3 cells, markedly decreased AMPK activity while increasing pS6, although the levels of pAKT remained unchanged (Figure 6d ). The same results were observed after inhibiting AMPK activity with CC in the clones expressing ectopic LKB1 (data not shown). It is of particular note that at 20 mM, CC substantially reduced pS6 levels, probably as a result of some unspecific effects of this compound at high concentrations. Thus, modulation of AMPK activity apparently did not affect PI3K signalling, which may be a finding of relevance to the eventual use of AMPK as a possible cancer therapy in LKB1 wild-type tumours.
Discussion
The presence of LKB1-inactivating mutations in cancer cells attests to their relevance in cancer development. A breakthrough in the understanding of LKB1 biological function was the identification of the energy sensor, AMPK, as an in vitro and in vivo substrate of LKB1 (Hawley et al., 2003; Woods et al., 2003) . In response to specific stresses, LKB1 phosphorylates and activates AMPK, which in turn activates TSC2-inhibiting signalling through mTOR (Corradetti et al., 2004; Shaw et al., 2004b) . The LKB1 role in AMPK activation has been demonstrated in cell-free systems, in some LKB1-deficient cancer cells such as HeLa and in mouse embryonic fibroblasts (MEFs) from Lkb1-knockout mice. Although LKB1-mutant lung cancer cells are able to phosphorylate AMPK to some extent, probably through the Ca 2 þ /CaM-dependent protein kinase kinase (CaMKK) (Hawley et al., 2005) , our observations unequivocally show that these cells are incapable of fully activating AMPK when energetically stressed, which is evidence in favour of a role for AMPK inactivation in lung carcinogenesis. AMPK becomes active in situations that increase the ratio of AMP/ATP, such as low glucose availability and hypoxia (Hardie, 2003) . This rarely occurs in normal cells under physiological conditions, with the exception of muscle cells. Our finding that some LKB1 wild-type lung primary tumours and cell lines have high endogenous AMPK activity implies that cancer cells are exposed to a considerably high AMP/ATP ratio, probably as a consequence of their continuous cell growth. The LKB1-specific adaptor protein, STRADa, which activates LKB1 and translocates it to the nucleus, is essential for LKB1 catalytic activity . Our observations reveal that STRADa protein is present in LKB1 wild-type but is almost undetectable in LKB1-mutant cells. The fact that STRADa levels can be restored following ectopic expression of wild-type LKB1 suggests that LKB1 promotes either STRADa transcription or STRADa protein stabilization. Likewise, STRADa protein is detectable in HeLa cells stably expressing wild-type LKB1 but not in control cells (Hawley et al., 2003) . Moreover, ectopic expression of STRADa induced LKB1 protein stabilization in a colon epithelial cell line stably expressing LKB1 (Baas et al., 2004) . Thus, it appears that STRADa and LKB1 regulate each other's protein levels, contributing to the overall activity of LKB1 in the complex and driving the localization of LKB1 within the cell. It is interesting to note that, whereas LKB1 localization is predominantly cytoplasmic in the primary tumours, LKB1 is detected in both cytoplasm and nucleus in the LKB1-stable transfectant cells. This implies that, in spite of stronger Lack of inhibition of mTOR activity by AICAR or glucose depletion in LKB1-deficient cells was described previously (Corradetti et al., 2004) . Here, we demonstrated that deficient LKB1 activity precludes the negative regulation of signalling through mTOR in response to the low availability of glucose in a variety of lung cancer cells, whereas does not affect the ability to respond to growth factors. Paradoxically, some tumour cells can tolerate glucose depletion to some extent if they are able to metabolize nonglycolytic bioenergetic substrates through AMPK (Elstrom et al., 2004; Buzzai et al., 2005) . In fact, complete activation of AMPK using AICAR in cells with constitutively active AKT prevented glucose depletion-mediated cell death (Elstrom et al., 2004; Plas and Thompson, 2005 ). Our observations demonstrate that this effect is dependent on the presence of LKB1 activity because AICAR treatment prevented cell death upon glucose depletion only in wild-type LKB1 cells. It is not clear, how LKB1-mutant cells are more resistant to mTOR inhibition, in response to glucose depletion, whereas they are more sensitive to cell death. The observation that AMPK activity facilitates tumour cell survival in LKB1 wild-type tumours and that some lung tumours carry increased AMPK activity indicate that inhibition of AMPK may be used as antineoplastic therapy in a subset of lung tumours. Supporting this hypothesis, reduction of AMPK levels was shown to decrease cell viability after glucose deprivation in human tumour cell lines (Kato et al., 2002) .
There is an inhibitory feedback loop of AKT activity due to sustained mTOR activation that triggers downregulation of the insulin receptor substrate-1 and -2 (IRS-1 and IRS-2) mediated by p70S6K (Manning, 2004) . Derived from this effect it has been shown that inhibition of mTOR in cancer cells and in patient tumours causes activation of AKT kinase and induction of IRS-1 (Sun et al., 2005; O'Reilly et al., 2006) . Moreover, TSC2-deficient cells are unable to activate AKT in response to growth factors, which may account for the low incidence of tumours induced by TSC2 deficiency in mice (Zhang et al., 2003; Manning et al., 2005) . Our data show that LKB1-deficient tumour cells retained the ability to activate AKT and mTOR in response to growth factors and that mTOR inhibition or activation driven by the modulation of AMPK activity does not lead to substantial changes in pAKT levels. These observations agree with the lack of AKT activation following ectopic expression of LKB1 (Corradetti et al., 2004) or with no changes in AMPK activity upon transformation with AKT (Buzzai et al., 2005) . In contrast, others detected AKT activation following AICAR treatment in both LKB1-mutant and wild-type MEFs (Shaw et al., 2004b) or other crosstalk between AMPK and PI3K/AKT signalling (Hahn-Windgassen et al., 2005; Tzatsos and Kandror, 2006) .
In conclusion, our present observations confirm the role of LKB1 in AMPK activation and the abrogation of energetic checkpoints in lung cancer cells to maintain energetically costly processes such as DNA replication and cell division. Finally, the distinct ability to activate AMPK yields differences in cell survival in response to energy deprivation among LKB1-mutant and LKB1 wild-type cells that could be exploited in cancer therapy.
Material and methods
Reagents, cell lines and lung primary tumours AICAR was obtained from Toronto Research Chemicals (North York, Canada), Rapamycin and LY-294002 from Sigma (St Louis, MO, USA) and compound C from Calbiochem (San Diego, CA, USA). The cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA), tested negative for mycoplasma infection and grown under recommended conditions. Thirtyseven lung primary tumours from formalin-fixed, paraffinembedded tissue blocks were used for the tissue microarray (TMA), as described previously (Conde et al., 2006) .
Generation of LKB1 monoclonal antibody
Two BALB/c mice were injected intraperitoneally (three times at 15-day intervals) with 100 mg MBP-LKB1 fusion protein plus Freund's adjuvant. See technical details as Supplementary methods (Mason et al., 1983) . The LKB1 antibody is now commercially available at Abcam, Cambridge, UK (code ab15095) and Santa Cruz Biotechnology (Santa Cruz, CA, USA) (code sc-32245).
Antibodies, Western blots and immunohistochemistry
Anti-phospho-ACC (S79), anti-phospho-AKT (S473), anti-AKT, anti-phospho AMPK (T172), anti-AMPK and antiphospho-S6 (S235/236) were obtained from Cell Signalling Technology (Beverly, MA, USA). Technical details of the Western blots are included as Supplementary methods. Immunohistochemical staining of LKB1 and phospho-acetyl CoA carboxylase (ACC) proteins was performed on 3-mm-thick sections from the TMA as described previously (Conde et al., 2006) . Immunostaining was evaluated by a pathologist (EC).
Cell culture, transfection and proliferations assays Cells were plated in culture flasks in DMEM (Invitrogen/ GIBCO, Grand Island, NY, USA) medium containing 10% (v/v) foetal bovine serum (FBS), 2 mM L-glutamine, 50 mg/ml penicillin/streptomycin and 2.5 mg/ml fungizone. Details of the cultures and transfection assays are included as Supplementary methods. For the cell proliferation assays, cells were seeded on 96-well plates at a density of 5000 cells/well and were allowed to grow for 24 h before adding the drugs. Cell death was determined as the percentage of propidium iodide-positive cells. For details see the Supplementary methods section. Each experimental condition was assayed in triplicate.
Immunocytochemical identification of LKB1 protein For subcellular localization of LKB1, we performed an immunocytochemical assay. A549 and H23 clones stably transfected with wild-type LKB1 were grown on coverslips After 24 h, the coverslips were fixed in cold methanol (2 min at À201C). The preparation was washed in PBS and blocked with 3% BSA/0.1% Triton X-100 in PBS. Monoclonal LKB1 antibody was diluted 1:50 and incubated for 1 h. Excess antibody was removed by washing three times in blocking medium. Labelling was revealed with anti-mouse IgG-Alexa488 (Molecular Probes, Eugene, OR, USA) at 1:200 and incubated for 1 h. All preparations were mounted with DePeX mounting medium (BDH Laboratory Supplies, Poole, UK).
